Hepatic Encephalopathy Management Alternatives

This guide reviews alternatives to rifaximin for managing hepatic encephalopathy (HE), a neuropsychiatric syndrome caused by liver dysfunction leading to elevated ammonia levels. The document outlines the classification of HE using the West Haven system, detailing grades from minimal changes in behavior to coma. It discusses pharmacologic treatment options, including lactulose, neomycin, and metronidazole, each with their mechanisms of action, dosing recommendations, and cost comparisons. Lactulose is emphasized as the first-line treatment due to its efficacy and favorable side effect profile. Neomycin and metronidazole are considered for patients who cannot tolerate lactulose, but their use is limited due to potential toxicity. The guide stresses the importance of monitoring patient response to treatment and suggests that rifaximin may be necessary if alternatives are ineffective. The document serves as a comprehensive resource for healthcare providers managing HE in hospice settings.